Supplementary Online Content

Inoue M, Tanboon J, Hirakawa S, et al. Association of dermatomyositis sine dermatitis with anti–nuclear matrix protein 2 autoantibodies. *JAMA Neurol*. Published online April 20, 2020. doi:10.1001/jamaneurol.2020.0673.

eTable 1. Autoantibodies used for immunohistochemistry

eTable 2. Factors associated with dermatomyositis sine dermatitis in patients with dermatomyositis on logistic regression analysis (adermopathic period > 2 years)

eTable 3. Factors associated with dermatomyositis sine dermatitis in patients with dermatomyositis on logistic regression analysis (for dermatomyositis sine dermatitis without a rash throughout available follow-up period)

eTable 4. Factors associated with dermatomyositis sine dermatitis in patients with dermatomyositis on logistic regression analysis (with perifascicular atrophy)

eTable 5. Factors associated with dermatomyositis sine dermatitis in patients with dermatomyositis on logistic regression analysis (with MAC deposition on capillaries)

This supplementary material has been provided by the authors to give readers additional information about their work.

eTable 1. Autoantibodies used for immunohistochemistry

Antibody	Clone	Dilution	Company
Human major histocompatibility complex class I (HLA-ABC)	W6/32	1:10,000	Thermo Fisher Scientific
Human major histocompatibility complex class II (HLA-DR)	B308	1:500	Affinity BioReagents
Membrane attack complex (C5b-9)	aE11	1:100	Dako
Myxovirus resistance protein A (Mx1/2/3)	H-285	1:200	Santa Cruz Biotechnology

HLA: human leukocyte antigen

eTable 2. Factors associated with dermatomyositis sine dermatitis in patients with dermatomyositis on logistic regression analysis (adermopathic period > 2 years)

Each category of disease duration denotes the following period: short (≤ 25th percentile, ≤ 1.5 months), middle (> 25th and ≤ 75th percentile, > 1.5 months and ≤ 6.5 months), and long (> 75th percentile, > 6.5 months). OR, odds ratio; CI,

	Unadjusted (n = 179)	
	OR (95%CI)	p value
NXP-2	20.33 (2.48-166.96)	.005
TIF1-γ	0.21 (0.03-1.69)	.14
Disease duration: Short (≤ 25th percentile)	1.00 [reference]	
Middle (> 25th and ≤ 75th percentile)	4.76 (0.57-39.86)	.15
Long (> 75th percentile)	1.16 (0.07-19.08)	.92

confidence interval; NXP-2, nuclear matrix protein 2; TIF1-γ, transcription intermediary factor 1 γ

eTable 3. Factors associated with dermatomyositis sine dermatitis in patients with dermatomyositis on logistic regression analysis (for dermatomyositis sine dermatitis without a rash throughout available

	Unadjusted (n = 182)		Adjusted (n = 182)[a]	
	OR (95%CI)	p value	OR (95%CI)	p value
NXP-2				
Age	1.01 (0.98-1.03)	.66	1.04 (1.00-1.08)	.05
Female	1.47 (0.40-5.38)	.56	0.57 (0.06-5.18)	.62
Disease duration: Short (≤ 25th percentile)	1.00 [reference]		1.00 [reference]	
Middle (> 25th and ≤ 75th percentile)	1.07 (0.27-3.75)	.99	0.46 (0.05-4.43)	.50
Long (> 75th percentile)	0.00 (0.00-infinity)	.99	0.00 (0.00-infinity)	.99
Perifascicular atrophy	5.17 (1.07-25.08)	.04	38.93 (3.49-434.42)	.003
NXP-2	21.96 (2.71-177.90)	.004	187.16 (8.80-3982.94)	.001
TIF1-γ				
Age	1.01 (0.98-1.03)	.66	1.01 (0.98-1.04)	.56
Female	1.47 (0.40-5.38)	.56	1.59 (0.34-7.53)	.56
Disease duration: Short (≤ 25th percentile)	1.00 [reference]		1.00 [reference]	
Middle (25th and 75th percentile)	1.07 (0.27-3.75)	.99	0.29 (0.05-1.67)	.17
Long (> 75th percentile)	0.00 (0.00-infinity)	.99	0.00 (0.00-infinity)	.99
Perifascicular atrophy	5.17 (1.07-25.08)	.04	16.09 (2.35-110.38)	.005
TIF1-γ	0.19 (0.02-1.51)	.12	0.11 (0.01-1.10)	.06

follow-up period)

[a] Adjusted for autoantibodies (NXP-2 or TIF1-γ) and disease duration. Each category of the disease duration includes the following period: short (≤ 25th percentile, ≤ 1.5 months), middle (> 25th and ≤ 75th percentile, > 1.5 months and ≤ 6 months), and long (> 75th percentile, > 6 months). OR, odds ratio; CI, confidence interval; NXP-2, nuclear matrix protein 2; TIF1-γ, transcription intermediary factor 1 γ

eTable 4. Factors associated with **dermatomyositis sine dermatitis in patients with dermatomyositis on logistic regression analysis (with perifascicular atrophy)**

	Unadjusted (n = 84)		Adjusted (n = 84)[a]	
	OR (95%CI)	p value	OR (95%CI)	p value
NXP-2				
Age	1.01 (0.98-1.03)	.65	1.04 (1.00-1.08)	.07
Female	0.90 (0.24-3.36)	.87	0.24 (0.03-1.92)	.18
Disease duration: Short (≤ 25th percentile)	1.00 [reference]		1.00 [reference]	
Middle (> 25th and ≤ 75th percentile)	0.29 (0.06-1.50)	.14	0.47 (0.06-3.54)	.47
Long (> 75th percentile)	0.22 (0.03-1.96)	.18	0.07 (0.00-1.22)	.07
NXP-2	20.67 (3.90-109.59)	.004	115.83 (7.32-1831.99)	.001
TIF1-γ				
Age	1.01 (0.98-1.03)	.66	1.01 (0.99-1.04)	.32
Female	0.90 (0.24-3.36)	.87	0.67 (0.15-2.92)	.59
Disease duration: Short (≤ 25th percentile)	1.00 [reference]		1.00 [reference]	
Middle (> 25th and ≤ 75th percentile)	0.29 (0.06-1.50)	.14	0.32 (0.06-1.80)	.20
Long (> 75th percentile)	0.22 (0.03-1.96)	.18	0.20 (0.02-1.84)	.15
TIF1-γ	0.13 (0.02-1.09)	.06	0.09 (0.01-0.83)	.03

[a]Adjusted for autoantibodies (NXP-2 or TIF1-γ) and disease duration. Each category of disease duration includes the following period: short (≤ 25th percentile, ≤ 3 months), middle (> 25th and ≤ 75th percentile, > 3 months and ≤ 9 months), and long (> 75th percentile, > 9 months). OR, odds ratio; CI, confidence interval; NXP-2, nuclear matrix protein 2; TIF1-γ, transcription intermediary factor 1 γ

eTable 5. Factors associated with dermatomyositis sine dermatitis in patients with dermatomyositis on logistic regression analysis (with MAC deposition on capillaries)

	Unadjusted (n = 165)		Adjusted (n = 165)[a]	
	OR (95%CI)	p value	OR (95%CI)	p value
NXP-2				
Age	1.01 (0.98-1.03)	.65	1.05 (1.01-1.09)	.02
Female	1.56 (0.49-4.98)	.45	0.58 (0.10-3.41)	.55
Disease duration: Short (≤ 25th percentile)	1.00 [reference]		1.00 [reference]	
Middle (> 25th and ≤ 75th percentile)	1.02 (0.31-3.40)	.98	0.93 (0.14-6.00)	.94
Long (> 75th percentile)	0.25 (0.03-2.26)	.22	0.04 (0.00-0.95)	.05
Perifascicular atrophy	3.18 (0.94-10.78)	.06	20.12 (2.54-159.28)	.004
NXP-2	27.65 (3.49-218.95)	.002	342.12 (15.23-7685.87)	<.001
TIF1-γ				
Age	1.01 (0.98-1.03)	.65	1.01 (0.99-1.04)	.36
Female	1.56 (0.49-4.98)	.45	1.51 (0.37-6.26)	.57
Disease duration: Short (≤ 25th percentile)	1.00 [reference]		1.00 [reference]	
Middle (25th and 75th percentile)	1.02 (0.31-3.40)	.98	0.38 (0.07-1.96)	.25
Long (> 75th percentile)	0.25 (0.03-2.26)	.22	0.08 (0.01-1.01)	.05
Perifascicular atrophy	3.18 (0.94-10.78)	.06	8.33 (1.70-40.90)	.009
TIF1-γ	0.12 (0.02-0.95)	.05	0.07 (0.01-0.68)	.02

[a]Adjusted for autoantibodies (NXP-2 or TIF1-γ) and disease duration. Each category of disease duration includes the following period: short (≤ 25th percentile, ≤ 1.5 months), middle (> 25th and ≤ 75th percentile, > 1.5 months and ≤ 6 months), and long (> 75th percentile, > 6 months). MAC, membrane attack complex; OR, odds ratio; CI, confidence interval; NXP-2, nuclear matrix protein 2; TIF1-γ, transcription intermediary factor 1 γ